Aeterna Zentaris to Present Preclinical Data for Anticancer Compounds Perifosine and AEZS-136 at Upcoming AACR Meeting

_{//health-fitness.news-articles.net/content/2012/ .. osine-and-aezs-136-at-upcoming-aacr-meeting.html}
^{Published in Health and Fitness on Monday, March 26th 2012 at 4:46 GMT by Market Wire}  

Aeterna Zentaris to Present Preclinical Data for Anticancer Compounds Perifosine and AEZS-136 at Upcoming AACR Meeting

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about AEZS

QUÉBEC CITY, March 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: [ AEZS ]) (TSX: AEZ) (the "Company") today announced poster presentations on two of its anticancer compounds, perifosine and AEZS-136, at the upcoming American Association for Cancer Research ("AACR") meeting to be held March 31 - April 4, 2012, at the McCormick Place in Chicago.

Sunday, April 1, 2012 / 1pm- 5pm (Central)

Monday, April 2, 2012 / 1pm- 5pm (Central)

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit [ www.aezsinc.com ].

SOURCE AETERNA ZENTARIS INC.